Aspirin inhibits epithelial-to-mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug

[1]  M. Fraga,et al.  The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors , 2016, Journal of Cell Science.

[2]  T. Das,et al.  Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. , 2015, Translational research : the journal of laboratory and clinical medicine.

[3]  S. Cagnol,et al.  Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer , 2014, Oncogene.

[4]  T. Das,et al.  Curcumin inhibits breast cancer stem cell migration by amplifying the E-cadherin/β-catenin negative feedback loop , 2014, Stem Cell Research & Therapy.

[5]  T. Das,et al.  Nuclear Matrix Protein SMAR1 Represses c-Fos-mediated HPV18 E6 Transcription through Alteration of Chromatin Histone Deacetylation* , 2014, The Journal of Biological Chemistry.

[6]  A. De,et al.  Inhibition of Epithelial to Mesenchymal Transition by E-cadherin Up-regulation via Repression of Slug Transcription and Inhibition of E-cadherin Degradation , 2014, The Journal of Biological Chemistry.

[7]  C. McCowan,et al.  Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study , 2014, British Journal of Cancer.

[8]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[9]  T. Das,et al.  Restoration of p53/miR‐34a regulatory axis decreases survival advantage and ensures Bax‐dependent apoptosis of non‐small cell lung carcinoma cells , 2014, FEBS letters.

[10]  T. Das,et al.  ROS-PIASγ cross talk channelizes ATM signaling from resistance to apoptosis during chemosensitization of resistant tumors , 2014, Cell Death and Disease.

[11]  S. Bhattacharyya,et al.  FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. , 2013, Immunity.

[12]  Jing Yang,et al.  Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.

[13]  J. Schmid,et al.  The complexity of NF-κB signaling in inflammation and cancer , 2013, Molecular Cancer.

[14]  Z. Miao,et al.  The inhibition of metastasis and growth of breast cancer by blocking the NF-κB signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles. , 2013, Biomaterials.

[15]  Mingzhao Wang,et al.  SLUG is activated by nuclear factor kappa B and confers human alveolar epithelial A549 cells resistance to tumor necrosis factor-alpha-induced apoptosis , 2013, World Journal of Surgical Oncology.

[16]  T. Das,et al.  Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways , 2013, Apoptosis.

[17]  Shuvomoy Banerjee,et al.  Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways , 2013, Apoptosis.

[18]  Jie-tao Ma,et al.  Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review , 2012, Cancer investigation.

[19]  M. Thun,et al.  The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.

[20]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[21]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[22]  T. Das,et al.  Restoration of tumor suppressor p53 by differentially regulating pro- and anti-p53 networks in HPV-18-infected cervical cancer cells , 2012, Oncogene.

[23]  Yoko Yamamoto,et al.  Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer , 2011, Diseases of the colon and rectum.

[24]  Philip Smith,et al.  Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1 , 2011, Oncogene.

[25]  L. Stark,et al.  c-Src dependency of NSAID-induced effects on NF-κB-mediated apoptosis in colorectal cancer cells. , 2011, Carcinogenesis.

[26]  Chang Gun Kim,et al.  The ETS Family Transcription Factor ELK-1 Regulates Induction of the Cell Cycle-regulatory Gene p21Waf1/Cip1 and the BAX Gene in Sodium Arsenite-exposed Human Keratinocyte HaCaT Cells* , 2011, The Journal of Biological Chemistry.

[27]  V. Patil,et al.  E-Cadherin as a diagnostic biomarker in breast cancer , 2011, North American journal of medical sciences.

[28]  A. Liss,et al.  Characterization of ATF2 in Rel/NFκB oncogenesis reveals its role in the regulation of Ras signaling , 2011, Small GTPases.

[29]  Jerzy Adamski,et al.  IKK&agr; controls canonical TGF&bgr;–SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in Panc1 cells , 2013, Journal of Cell Science.

[30]  D. Djakiew,et al.  NSAID Inhibition of Prostate Cancer Cell Migration Is Mediated by Nag-1 Induction via the p38 MAPK-p75NTR Pathway , 2010, Molecular Cancer Research.

[31]  L. Staudt,et al.  Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells , 2010, Oncogene.

[32]  S. Bhattacharyya,et al.  Gain of Cellular Adaptation Due to Prolonged p53 Impairment Leads to Functional Switchover from p53 to p73 during DNA Damage in Acute Myeloid Leukemia Cells* , 2010, The Journal of Biological Chemistry.

[33]  J. Blenis,et al.  ERK2/Fra1/ZEB pathway induces epithelial-to-mesenchymal transition , 2010, Cell cycle.

[34]  L. Ghibelli,et al.  The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies , 2010, International journal of cell biology.

[35]  L. Lahiry,et al.  Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. , 2010, Carcinogenesis.

[36]  M. Amin,et al.  KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine , 2010, Advances in anatomic pathology.

[37]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[38]  K. Schrör.  Clinical Applications of Aspirin , 2009 .

[39]  L. Heasley,et al.  Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. , 2008, Molecular biology of the cell.

[40]  A. Schwartz,et al.  Regular Adult Aspirin Use Decreases the Risk of Non-Small Cell Lung Cancer among Women , 2008, Cancer Epidemiology Biomarkers & Prevention.

[41]  Héctor Peinado,et al.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? , 2007, Nature Reviews Cancer.

[42]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[43]  T. Ogihara,et al.  Aspirin prevents adhesion of T lymphoblasts to vascular smooth muscle cells , 2007, FEBS letters.

[44]  T. Gilmore,et al.  Inhibitors of NF-κB signaling: 785 and counting , 2006, Oncogene.

[45]  R. Cameron,et al.  Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. , 2006, Cancer research.

[46]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[47]  E. Giovannucci,et al.  Aspirin use and lung cancer in men , 2003, British Journal of Cancer.

[48]  A. Baldwin,et al.  Oncoprotein Suppression of Tumor Necrosis Factor-induced NFκB Activation Is Independent of Raf-controlled Pathways* , 2003, Journal of Biological Chemistry.

[49]  J. McCubrey,et al.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention , 2003, Leukemia.

[50]  H. Nakshatri,et al.  NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4* , 2003, Journal of Biological Chemistry.

[51]  M. Mareel,et al.  Clinical, cellular, and molecular aspects of cancer invasion. , 2003, Physiological reviews.

[52]  M. Fraga,et al.  The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors , 2003, Journal of Cell Science.

[53]  F. Sladek,et al.  MAP kinase phosphorylation‐dependent activation of Elk‐1 leads to activation of the co‐activator p300 , 2003, The EMBO journal.

[54]  G. Bepler,et al.  Regular aspirin use and lung cancer risk , 2002, BMC Cancer.

[55]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[56]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  E. Fearon,et al.  The SLUG zinc-finger protein represses E-cadherin in breast cancer. , 2002, Cancer research.

[58]  M. Nieto,et al.  The snail superfamily of zinc-finger transcription factors , 2002, Nature Reviews Molecular Cell Biology.

[59]  A. Aplin,et al.  Integrin-Mediated Adhesion Regulates ERK Nuclear Translocation and Phosphorylation of Elk-1 , 2001, The Journal of cell biology.

[60]  R. Gaynor,et al.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. , 2001, The Journal of clinical investigation.

[61]  S. Thorgeirsson,et al.  Role of the IκB Kinase Complex in Oncogenic Ras- and Raf-Mediated Transformation of Rat Liver Epithelial Cells , 2000, Molecular and Cellular Biology.

[62]  Hong Zhang,et al.  NF-κB is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis , 2000, Oncogene.

[63]  C. Martínez-A,et al.  Ras Proteins: Recent Advances and New Functions , 1999 .

[64]  A. Norrish,et al.  Non‐steroidal anti‐inflammatory drugs and prostate cancer progression , 1998, International journal of cancer.

[65]  A. Sharrocks,et al.  The Elk-1 ETS-Domain Transcription Factor Contains a Mitogen-Activated Protein Kinase Targeting Motif , 1998, Molecular and Cellular Biology.

[66]  C. Der,et al.  Oncogenic Ha-Ras-induced Signaling Activates NF-κB Transcriptional Activity, Which Is Required for Cellular Transformation* , 1997, The Journal of Biological Chemistry.

[67]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[68]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[69]  W. Birchmeier,et al.  E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells , 1991, The Journal of cell biology.

[70]  Y. Cheng,et al.  FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction , 2017, Oncogene.

[71]  D. Djakiew,et al.  Signaling and Regulation NSAID Inhibition of Prostate Cancer Cell Migration Is Mediated by Nag-1 Induction via the p 38 MAPK-p 75 NTR Pathway , 2010 .

[72]  A. Baldwin,et al.  Requirement of the NF- κ B Subunit p65/RelA for K-Ras – Induced Lung Tumorigenesis , 2010 .

[73]  C. Martínez-A,et al.  Ras proteins: recent advances and new functions. , 1999, Blood.